

# Journal Pre-proof



## Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's

Augustine S. Lee, MD, R. Hal Scofield, MD, Katherine Morland Hammitt, MA, Nishant Gupta, MD, Donald E. Thomas, MD, Teng Moua, MD, Kamonpun Ussavarungsi, MD, E. William St. Clair, MD, Richard Meehan, MD, Kieron Dunleavy, MD, Matt Makara, MPH, Steven E. Carsons, MD, Nancy L. Carteron, MD, in senior position

PII: S0012-3692(20)34902-3

DOI: <https://doi.org/10.1016/j.chest.2020.10.011>

Reference: CHEST 3696

To appear in: *CHEST*

Received Date: 30 April 2020

Revised Date: 21 September 2020

Accepted Date: 2 October 2020

Please cite this article as: Lee AS, Scofield RH, Hammitt KM, Gupta N, Thomas DE, Moua T, Ussavarungsi K, St. Clair EW, Meehan R, Dunleavy K, Makara M, Carsons SE, Carteron NL, Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's, *CHEST* (2020), doi: <https://doi.org/10.1016/j.chest.2020.10.011>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Copyright © 2020 Published by Elsevier Inc under license from the American College of Chest Physicians.

**Word Count for Manuscript: 3,178**

**TITLE:**

**Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's**

**SHORT TITLE:** Guidelines for Pulmonary Disease in Sjögren's

**AUTHOR LIST:**

Augustine S. Lee, MD  
R. Hal Scofield, MD  
Katherine Morland Hammitt, MA  
Nishant Gupta, MD  
Donald E. Thomas, MD  
Teng Moua, MD  
Kamonpun Ussavarungsi, MD  
E. William St. Clair, MD  
Richard Meehan, MD  
Kieron Dunleavy, MD  
Matt Makara, MPH  
Steven E. Carsons, MD and Nancy L. Carteron, MD (*in senior position*)

**Authors Listed by Last Name and Initial/s:** Lee AS<sup>1</sup>, Scofield RH<sup>2</sup>, Hammitt KM<sup>3</sup>, Gupta N<sup>4</sup>, Thomas DE<sup>5</sup>, Moua T<sup>6</sup>, Ussavarungsi K<sup>7</sup>, St Clair EW<sup>8</sup>, Meehan R<sup>9</sup>, Dunleavy K<sup>10</sup>, Makara M<sup>3</sup>, Carsons SE<sup>11</sup> and Carteron NL<sup>12</sup>

**INSTITUTIONS:**

1. Mayo Clinic, Jacksonville, FL
2. Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; and Medical and Research Services, Oklahoma City Department of Veterans Affairs Medical Center, Oklahoma City, OK
3. Sjögren's Foundation, Reston, VA
4. University of Cincinnati and VA Medical Center, Cincinnati, OH
5. Uniformed Services University of the Health Sciences, Bethesda, MD, and Arthritis and Pain Associates of Prince Georges County, MD
6. Mayo Clinic, Rochester, MN
7. University of Iowa Health Care, Carver College of Medicine, Iowa City, IA
8. Duke University Medical Center, Durham, NC
9. National Jewish Health, Denver, CO
10. George Washington University Cancer Center, Washington, D.C.
11. New York University Winthrop Hospital and NYU Langone Health, New York
12. University of California Berkeley and San Francisco, CA

**CORRESPONDENT:**

Katherine Morland Hammitt, Sjögren's Foundation, 10701 Parkridge Blvd, Ste 170, Reston, VA 20191, khammitt@sjogrens.org

**IN COLLABORATION WITH the Consensus Expert Panel** (Members listed in e-Appendix 4; Our sincere hope is that these members can be listed and made searchable in PubMed)

**WITH SPECIAL THANKS** to Former Topic Review Group participants: Herbert S. B. Baraf, MD, Arthritis and Rheumatism Associates, P.C., and George Washington University and University of Maryland; and Joseph P. Lynch, MD, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA); Rebecca Landau, MLS, Librarian, and formerly, Health Sciences Library, Penn Presbyterian Medical Center, Philadelphia, PA; the American Society of Clinical Oncology (ASCO) and especially Patricia Hurley, MSc, CPHQ, for identifying a hematologist/oncologist for the TRG and providing methodology materials; and the American College of Rheumatology and especially Amy Miller Turner for guidance on methodology and guidelines review.

**SUMMARY OF CONFLICT OF INTEREST STATEMENTS:**

**A.S. Lee:** None; **R.H. Scofield:** None; **K.M. Hammitt:** None; **Gupta N:** None; **D.E. Thomas:** None; **T Moua:** None; **Ussavarungsi K:** None; **E.W. St Clair:** Abbvie, BMS, Viela Bio, Rheos Medicines; **R. Meehan:** None; **Dunleavy K:** Abbvie, Astra Zeneca, Amgen, Celgene, Pharmacyclics, Adaptive, Seattle Genetics, Kite, Janssen, MorphoSys; **M. Makara:** None; **S.E. Carsons:** Novartis, Roche and **N.L. Carteron:** BMS, Gilead, Medtronic.

**FUNDING:**

The Sjögren's Foundation Clinical Practice Guidelines are supported by the Foundation with no industry funding. No compensation was paid for study participation.

**PRIOR ABSTRACT PUBLICATION/PRESENTATION:**

An abstract on the formation of the Topic Review Group and areas to be covered was presented in a poster format at the 2018 International Symposium on Sjögren's Syndrome (ISSS) in Washington, D.C. A poster was accepted for the May 2020 ATS annual meeting, which was rescheduled as a virtual meeting. An updated poster was uploaded on 7/30/2020 for the later meeting.

**DISCLAIMERS:** The Sjögren's Foundation developed Clinical Practice Guidelines with an expert group of rheumatologists and pulmonologists and an oncologist to help guide ALL healthcare providers in managing and treating pulmonary manifestations of Sjögren's patients. They are not intended to prescribe care for individual patients and may not apply to certain clinical scenarios or take into account the nuances of clinical care. These guidelines are intended for Sjögren's and lung disease and may not apply to those with other systemic autoimmune disorders. Clinicians are asked to weigh various factors including unique patient-specific nuances, patient preferences, and cost, in their decision-making when considering these Recommendations.

**ABBREVIATIONS:**

Agency for Health Research and Quality (AHRQ)  
American College of Rheumatology (ACR)  
American-European Consensus Group (AECG)

American Society of Clinical Oncology (ASCO)  
Azathioprine (AZA)  
Bronchoalveolar Lavage (BAL)  
Centers for Disease Control (CDC)  
Chest X-Ray (CXR)  
Chronic Thromboembolic Pulmonary Hypertension (CTEPH)  
Computed Tomographic Pulmonary Angiogram (CTPA)  
Connective Tissue Disease (CTD)  
Consensus Expert Panel (CEP)  
Cyclophosphamide (CYP)  
Diffuse Cystic Lung Disease (DCLD)  
Diffusing Capacity of Lung for Carbon Monoxide (DLCO)  
EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)  
European League Against Rheumatism (EULAR)  
Follicular Bronchiolitis (FB)  
Forced Vital Capacity (FVC)  
Gastroesophageal Reflux Disease (GERD)  
Grading of Recommendations Assessment, Development and Evaluation (GRADE)  
High Frequency Chest Wall Oscillation (HFCWO)  
High Resolution Computed Tomography (HRCT)  
Interstitial Lung Disease (ILD)  
Lymphoid Interstitial Pneumonia (LIP)  
Mucosa-Associated Lymphoid Tissue (MALT)  
Mycophenolate Mofetil (MMF)  
Non-Tuberculous Mycobacterium (NTM)  
Nonspecific Interstitial Pneumonia (NSIP)  
Obstructive Sleep Apnea (OSA)  
Organizing Pneumonia (OP)  
Partial Pressure of Oxygen in Arterial Blood (PaO<sub>2</sub>)  
Patient, Intervention, Comparison, Outcome (PICO)  
Positive Airway Pressure (PAP)  
Positive Expiratory Pressure (PEP)  
Positron Emission Tomography (PET)  
Pulmonary Function Test (PFT)  
Pulmonary Hypertension (PH)  
Quality of Life (QOL)  
Rituximab (RTX)  
Standardized Uptake Value (SUV)  
Topic Review Group (TRG)  
Thiopurine Methyltransferase (TPMT)  
Usual Interstitial Pneumonia (UIP)  
U.S. Preventive Services Task Force (USPSTF)  
Ventilation-Perfusion (VQ)

**Word Count for Abstract: 288****Abstract**

**Objective.** Pulmonary disease is a potentially serious yet underdiagnosed complication of Sjögren's syndrome, the second most common autoimmune rheumatic disease. Approximately 16% of patients with Sjögren's demonstrate pulmonary involvement with higher mortality and lower quality of life. Clinical practice guidelines for pulmonary manifestations of Sjögren's were developed by the Sjögren's Foundation after identifying a critical need for early diagnosis and improved quality and consistency of care.

**Methods.** A rigorous and transparent methodology was followed according to American College of Rheumatology (ACR) guidelines. The Pulmonary Topic Review Group (TRG) developed clinical questions in the PICO (Patient, Intervention, Comparison, Outcome) format and selected literature search parameters. Each article was reviewed by a minimum of two TRG members for eligibility and assessment of quality of evidence and strength of recommendation. Guidelines were then drafted based on available evidence, expert opinion, and clinical importance. Draft recommendations with a clinical rationale and data extraction tables were submitted to a Consensus Expert Panel (CEP) for consideration and approval, with at least 75% agreement required for individual recommendations to be included in the final version.

**Results.** The literature search revealed 1,192 articles, of which 150 qualified for consideration in guideline development. Of the original 85 PICO questions posed by the TRG, 51 recommendations were generated. These were then reviewed by the CEP and 51 recommendations were finalized, with a mean agreement of 97.71% (range 79-100%). The recommendations span topics of evaluating Sjögren's patients for pulmonary manifestations and assessing, managing and treating upper and lower airway disease, interstitial lung disease, and lymphoproliferative disease.

**Conclusion.** Clinical practice guidelines for pulmonary manifestations in Sjögren's will improve early identification, evaluation, and uniformity of care by primary care physicians, rheumatologists and pulmonologists. Additionally, opportunities for future research are identified.

## MANUSCRIPT

### Introduction

Pulmonary disease is a potentially serious yet underdiagnosed complication of Sjögren's, syndrome, a chronic autoimmune disease with substantial disease morbidity and burden as well as reduced quality of life.<sup>1,2</sup> Sjögren's not occurring with another autoimmune disease has a prevalence second only to rheumatoid arthritis among the inflammatory rheumatic illnesses,<sup>3</sup> and although the disease can be observed in children and men,<sup>4</sup> it is most prevalent in women.<sup>5</sup>

Clinical practice guidelines for the diagnosis, management and treatment of pulmonary manifestations of Sjögren's were developed by the Sjögren's Foundation after identifying a critical need for early diagnosis and improved quality and consistency of care. Approximately 10-20% of Sjögren's patients demonstrate pulmonary involvement with an associated higher mortality and lower quality of life (QOL).<sup>6-11</sup> Additionally, up to 65% of asymptomatic Sjögren's patients will have abnormal pulmonary imaging,<sup>7</sup> emphasizing the need for provider awareness of pulmonary manifestations and education on evaluation, monitoring and treatment. Pulmonologists are encouraged to consider the possibility of Sjögren's in patients with pulmonary disease who have not previously been diagnosed as having Sjögren's. As such, pulmonologists can play an important role in Sjögren's diagnosis and ensure non-pulmonary complications of Sjögren's are addressed by the appropriate specialists.

### Methods

A rigorous and transparent methodology was followed according to the American College of Rheumatology (ACR) guidelines.<sup>12</sup> The methodology employed for these guidelines was first developed and used by the Foundation for recommendations for rheumatologic management in Sjögren's<sup>13</sup> and included direction from ACR as well as other guidelines

methodology consultants.<sup>14</sup> The Pulmonary Topic Review Group (TRG) included equal parts rheumatologists and pulmonologists (n=4 each) and one hematologist-oncologist as well as participation and oversight by a rheumatologist chair for all Foundation guidelines and a rheumatology/systemic symptoms guidelines chair. The TRG defined systematic review parameters and endpoints (e-Appendix 1), including MEDLINE/PubMed peer-reviewed articles in English between January 1, 1990 and February 1, 2020, and studies with Sjögren's patients classified or diagnosed by any published set of criteria. Although currently either the 2002 AECG (American-European Consensus Group)<sup>15</sup> or the 2016 ACR/EULAR (American College of Rheumatology/European League Against Rheumatism)<sup>16</sup> classification criteria for primary Sjögren's are utilized most often, a number of criteria have been used historically.

An outline with clinical questions was developed based on the PICO (Patient, Intervention, Comparison, Outcome) format (e-Appendix 2). For the systematic review, literature search terms were compiled by the TRG, and the searches were executed by a librarian (e-Appendix 1). Each article was reviewed by a minimum of two TRG members for eligibility and assessment of quality of evidence. Full data was extracted into four tables: Study Characteristics, Sample and Disease, Evidence, and Quality ( <https://www.sjogrens.org/researchers-providers/clinical-practice-guidelines>). The Quality table rated the overall quality of each study according to criteria related to study design and the risk of bias used in recommendation development.

Guidelines were drafted based on available evidence using a strength of the evidence rating (e-Appendix 3), the expertise of the TRG and Consensus Expert Panel (CEP) members who reviewed the recommendations, and clinical importance. Each recommendation also was rated for the strength of the recommendation, which was gauged by the TRG based on a

combination of available evidence as well as the confidence level that the recommendation offers the best current guidance for practice (e-Appendix 3).

Draft recommendations and strength of the recommendation were submitted to the CEP for consideration and approval, with at least 75% agreement required for inclusion in the manuscript. A clinical rationale for each recommendation and data extraction tables for articles used in developing the recommendations also were provided. The CEP, comprised of 68 members, including 40 rheumatologists, 21 pulmonologists, and 7 additional members, all of whom were Sjögren's patients or family of patients (e-Appendix 4), voted on each recommendation using a 6-point Likert scale, the strength of the recommendation (rating), and provided commentary for TRG review. If the consensus threshold was not met, the recommendation would be adjusted by the TRG until the consensus threshold was met. The commentary provided by the CEP was considered in the final wording of the recommendations and clinical rationales. Recommendations were again evaluated by the CEP following minor wording changes to better align with standard guideline language..

The formal consensus process was deemed especially critical in view of the lack of high-quality evidence. The guidelines committee utilized principles of the American Society of Clinical Oncology (ASCO), GRADE (Grading of Recommendations Assessment, Development and Evaluation), Agency for Health Research and Quality (AHRQ) and the U.S. Preventive Services Task Force (USPSTF) to formulate the methodology.

## **Results**

The TRG originally developed 85 topics/questions in the PICO format that spanned epidemiology, evaluation, diagnostics, and therapeutics of Sjögren's-related pulmonary manifestations including upper and lower airway disorders, interstitial lung diseases, pulmonary



vascular disease, and lymphoproliferative disorders. The number of questions was reduced after TRG members ranked all clinical questions as Primary, Secondary or Minor in terms of the question's importance for recommendation development, and final selection was determined by TRG leadership when consensus was lacking. Following the literature search, some PICO questions were determined to be irrelevant and/or not suited to recommendations for a pulmonary condition or to be within the scope of this paper.

Medical literature searches utilizing the pre-defined search terms and search criteria (e-Appendix 1) identified 1,192 articles of which 178 abstracts were selected and 150 of those deemed qualified for data extraction and use in guideline development. Abstracts identified by the literature search but eliminated by the TRG were excluded for the following reasons: not relevant to guidelines (such as unrelated to Sjogren's and/or pulmonary), article type (commentary, editorial, letter to the editor), case studies that provided no unique information, or were not in English (e-Appendix 1, Quorum Diagram).

The TRG then generated 51 recommendations along with a rating on the strength of each recommendation that was submitted to the CEP. A clinical rationale for each recommendation (e-Appendix 5) and all references with data extracted were provided in support of the recommendations. The consensus threshold of 75% was achieved for all 51 recommendations and ratings in one round, with agreement ranging from 79% to 100% for 102 questions (51 recommendations and 51 ratings) and an average agreement of close to 98%. The CEP results are provided in e-Appendix 4. Additionally, commentaries provided by the CEP were reviewed by the TRG and led to rewording 12 recommendations and 13 clinical rationales without altering their substance. Because these recommendations were intended to be wide-reaching and used

across multiple specialties, the authors preferred to make firm recommendations and avoided vaguer terms such as “may be considered” when reasonable.

### **Evaluation for lung involvement**

Consensus recommendations on evaluating Sjögren’s patients for potential pulmonary signs and symptoms and the use of imaging, full (complete) pulmonary function tests (PFTs), which includes spirometry, diffusing capacity of the lung for carbon monoxide (DLCO), and lung volumes ideally measured by body plethysmography, and bronchoscopy are listed in Table 1 and Figure 1. In addition, we have provided practical clinical guides to assist in the history taking and symptom detection for evaluation purposes in e-Appendix 6. An additional consideration that was borne out of the literature review was that Sjögren’s is often diagnosed after a pulmonary disorder is initially recognized. These include patients with airway disorders (e.g. refractory cough, small airway disease), indeterminate interstitial lung diseases (ILD), and pulmonary lymphoproliferative disorders (e.g. mucosa-associated lymphoid tissue, or, MALT, type lymphoma). Table 2 provides a list of Sjögren’s symptoms for the clinician to consider when the etiology of a patient’s pulmonary condition remains undiagnosed.

Since lung involvement is common in Sjögren’s, a baseline chest x-ray (CXR) is recommended. If concern is high for lung involvement, however, a high-resolution computed tomography or CT (HRCT) scan may be preferred due to its higher sensitivity and specificity.<sup>17-</sup>  
<sup>18</sup> Full PFTs as described above may additionally identify patients with subclinical Sjögren’s lung disease.<sup>19</sup> Although little outcomes data exist, a baseline CXR and full PFTs were recommended by the TRG and the CEP when weighing the risks and benefits, as these tests are likely to aid in identifying subclinical disease, in future comparisons when symptoms develop, and in guiding the timing of any specific interventions.

In general, all symptomatic patients should have serial clinical and PFT monitoring. However, monitoring strategy depends on the clinician's consideration of the specific condition, its severity, the patient's symptoms and functional status, and the pace of clinical deterioration.

While no specific guidance regarding intervals for repeat testing can be given, the majority of TRG members repeat PFTs at least every 6-12 months to better understand longitudinal disease trajectory. Typically, spirometry is performed as the main monitoring test at each interval, with complete PFTs, which include lung volumes and DLCO performed at longer intervals.

**Table 1: Recommendations for Evaluating Sjögren's Patients**

<b>Recommendations: Evaluating Asymptomatic Sjögren's Patients for Pulmonary Complications</b>	<b>Strength of Evidence</b>	<b>Strength of Recommendation</b>
1. Serologic biomarkers must not be employed to evaluate for pulmonary involvement in patients with established Sjögren's disease.	INTERMEDIATE	STRONG
2. Due to the prevalence of respiratory involvement in Sjögren's, clinicians must obtain a detailed medical history inquiring about respiratory symptoms in all Sjögren's patients at the initial and every subsequent visit.	HIGH	STRONG
3. In Sjögren's patients without respiratory symptoms, a baseline two-view chest x-ray (CXR) may be performed. The baseline chest radiograph can 1) help identify pulmonary involvement despite the absence of symptoms, 2) identify alternate etiologies of sicca symptoms such as sarcoidosis, vasculitis, and lymphoma, and 3) serve as a baseline for future comparisons.	INTERMEDIATE	WEAK
4. In Sjögren's patients who have no respiratory symptoms, baseline complete pulmonary function tests (PFTs)* may be considered to evaluate for the presence of underlying pulmonary manifestations. PFTs should include pre- and post-bronchodilator spirometry, lung volumes, and diffusing capacity of the lung for carbon monoxide (DLCO). Abnormalities identified may require further corroboration with advanced testing.	INTERMEDIATE	WEAK
5. In asymptomatic Sjögren's patients, routine	INTERMEDIATE	STRONG

echocardiogram is not recommended.		
<b>Recommendations:</b>		
<b>Evaluating Sjögren's Patients with Pulmonary Symptoms</b>	<b>Strength of Evidence</b>	<b>Strength of Recommendation</b>
1A. In Sjögren's patients with chronic cough and/or dyspnea, complete PFTs and HRCT should be done to evaluate for pulmonary involvement.	INTERMEDIATE	MODERATE
1B. In a Sjögren's patient with respiratory symptoms, the interval for repeat HRCT and PFTs must be determined on a case-by-case basis and individualized according to the nature and severity of the underlying pulmonary abnormality and the degree of symptoms and functional impairment.	INSUFFICIENT	STRONG
2. In a Sjögren's patient with dyspnea, an echocardiogram is recommended in the following circumstances: <ul style="list-style-type: none"> <li>1) In patients with suspected pulmonary hypertension (PH)</li> <li>2) In patients with unexplained dyspnea after pulmonary etiologies (asthma, small airways disease, bronchiectasis, ILD) have been excluded</li> <li>3) In patients with suspected cardiac involvement</li> </ul>	HIGH	STRONG
3. In a Sjögren's patient with respiratory symptoms, a computed tomography pulmonary angiogram (CTPA) to look for pulmonary embolism must not be performed routinely in all patients but rather dictated by clinical suspicion for pulmonary embolism in individual circumstances. If clinically concerned about a pulmonary embolism, CTPA is the confirmatory test of choice. Ventilation-perfusion (VQ) scan should only be considered in the following circumstances: <ul style="list-style-type: none"> <li>1) To rule out chronic thromboembolic pulmonary hypertension (CTEPH) in patients with PH</li> <li>2) When clinical concern for pulmonary embolism exists, and a physician is unable to do a CTPA because of patient allergy to contrast or renal insufficiency</li> </ul>	LOW	STRONG
<b>Recommendations:</b>	<b>Strength of Evidence</b>	<b>Strength of Recommendation</b>

<b>Evaluating for Sjögren's in Patients with Lung Disease</b>		
1. In patients who have an uncharacterized ILD, diffuse cystic lung disease (DCLD), or pulmonary lymphoma, clinical and serologic evaluation for Sjögren's is recommended.	HIGH	STRONG
<b>Recommendations: Use of Bronchoscopy</b>	<b>Strength of Evidence</b>	<b>Strength of Recommendation</b>
1. In a Sjögren's patient with respiratory symptoms, bronchoscopy with bronchoalveolar lavage (BAL) must not be performed routinely but determined on a case-by-case basis and limited to special circumstances, such as the need to: <ol style="list-style-type: none"> <li>1) Rule out infectious etiologies, especially in patients on immune suppression</li> <li>2) Rule out endobronchial abnormalities such as amyloidosis in patients with chronic cough not otherwise responsive to treatment</li> <li>3) Distinguish between other etiologies of sicca symptoms such as sarcoidosis</li> </ol>	LOW	STRONG
2. In a Sjögren's patient with respiratory symptoms, use of bronchoscopy with endobronchial biopsies and transbronchial lung biopsy are not recommended for routine use.	INSUFFICIENT	STRONG

**Figure 1: Respiratory Evaluation for Sjögren's Patients** (provided in jpg file)

**Legend:**

\* The benefit of obtaining baseline PFTs in asymptomatic Sjögren's patients with regards to long-term outcomes is not clear. This paucity of evidence and the potential costs of the test should be taken into account and discussed with individual patients prior to proceeding with PFTs.

Complete PFTs includes spirometry, diffusing capacity of the lung for carbon monoxide (DLCO), lung volumes, ideally measured by body plethysmography

Abbreviations: CXR=Chest X-Ray; HRCT=High Resolution Computed Tomography; PFTs=Pulmonary Function Tests; DLCO=Diffusing Capacity of Lung for Carbon Monoxide

**Table 2: Evaluating for Potential Sjögren's in Patients with Pulmonary Symptoms**  
Symptoms should prompt physician to engage in further serologic evaluation and/or rheumatology consultation.

<b>Symptoms</b>	<b>Questions to Ask Patient</b>
Oral Symptoms	<ul style="list-style-type: none"> <li>• Does your mouth feel dry?</li> <li>• Do you need liquids to swallow dry foods?</li> <li>• Do you frequently sip/drink water?</li> <li>• Do you have a burning sensation in the mouth?</li> <li>• Do you have painful sores or red patches at the corners of the mouth (angular cheilitis)?</li> <li>• Do you get frequent dental cavities, particularly gumline cavities?</li> <li>• Do your teeth tend to chip, crack, and/or erode on the surfaces?</li> <li>• Do you suffer from gum inflammation or receding gums (gingivitis)?</li> </ul>
Ocular Symptoms	<ul style="list-style-type: none"> <li>• Do your eyes frequently feel dry, irritated, itchy, or painful?</li> <li>• Do you have a sensation that there might be a foreign body in your eye?</li> <li>• Are your eyes light sensitive?</li> <li>• Do you frequently use eye drops for irritation or dryness?</li> <li>• Is your vision frequently blurry, or do you have unexplained vision changes?</li> </ul>
Other Symptoms	<ul style="list-style-type: none"> <li>• Have you noticed gland swelling in your face or along the jaw line (swollen parotid and/or submandibular glands)?</li> <li>• Do you suffer dryness of the vagina (Is intercourse painful?) or skin (Is your skin itchy or flaking)?</li> <li>• Do your feet, legs or hands ever feel numb, have a change in sensation, or have burning pain (peripheral neuropathy)?</li> <li>• Do you suffer from extreme fatigue?</li> <li>• Do your joints or muscles ache when you are not sick (arthralgias, myalgias)?</li> <li>• Do you ever notice your fingers turning pale or blue in the cold (Raynaud's)?</li> </ul>

### Upper and lower airway disorders

Upper and lower airway disease reported in association with or as a result of Sjögren's includes xerotrachea, dysphagia, laryngopharyngeal reflux, vocal cord cystic lesions ('bamboo nodules'), obstructive sleep apnea (OSA), bronchiectasis, bronchiolitis, obstructive lung disease and reactive airway disease. Approximately 38% of Sjögren's patients have chronic cough.<sup>20</sup> Interestingly, among patients without an initial Sjögren's diagnosis, an unexplained cough

associated with dry eyes led to confirmation of Sjögren's in 36%.<sup>21</sup> An evaluation is warranted in a Sjögren's patient with chronic cough (>8 weeks), starting with an assessment for common causes (e.g. asthma, gastroesophageal reflux disease or GERD, upper airway cough syndrome, non-asthmatic eosinophilic bronchitis),<sup>22</sup> followed by evaluation of pulmonary complications of Sjögren's, including xerotrachea, ILD, bronchiolitis, bronchiectasis, and pulmonary lymphoma.

Small airway disease in the setting of Sjögren's may represent histopathologic follicular or constrictive bronchiolitis.<sup>23</sup> Although there is often overlap on imaging and physiology, these distinctive histologic findings have variable types of inflammation (neutrophilic, lymphocytic, eosinophilic, fibroblast) and bronchiolocentric fibrosis. Bronchiectasis is characterized radiographically by the atypical dilation of the airways larger than the accompanying bronchial artery, or visible to 1 cm of the costal pleural margin. Inhaled corticosteroids, while possibly increasing the risk for candidiasis, have been recommended for inflammatory airway disease by the 2020 EULAR recommendations for managing Sjögren's.<sup>24</sup> Bronchodilators may be tried empirically. And, while no broadly accepted criteria exist for xerotrachea, after exclusion of other causes of cough, empirical humidification in all Sjögren's patients with chronic cough is recommended along with consideration of an empiric trial of a secretagogue and/or guaifenesin. Most of these and other recommendations as listed in Table 3 largely draw upon experience from related airway disorders outside of the specific context of Sjögren's. Figure 2 is a suggested clinical pathway based on these recommendations.

**Table 3: Recommendations for Assessment and Management of Upper and Lower Airway Disease in Sjögren's Patients**

<b>Recommendations: Assessment and Management of Upper and Lower Airway Disease in Sjögren's Patients</b>	<b>Strength of Evidence</b>	<b>Strength of Recommendation</b>
1. In Sjögren's patients with symptomatic vocal cord	LOW	MODERATE

cystic lesions ('bamboo nodules'), less aggressive interventions including voice therapy, inhaled corticosteroids, or intralesional corticosteroid injection, should be tried first. Surgical resection should be considered if initial measures fail, with consultation by a laryngologist with experience in Sjögren's.		
2. Sjögren's patients with dry bothersome cough and documented absence of lower airway or parenchymal lung disease must be assessed for treatable or preventable etiologies other than xerotrachea, including gastroesophageal reflux, post-nasal drip and asthma.	INTERMEDIATE	STRONG
3. In a Sjögren's patient with dry, nonproductive cough, humidification, secretagogues, and guaifenesin may be empirically initiated after exclusion of other causes.	INSUFFICIENT	WEAK
4. The use of humidification for improving positive airway pressure (PAP) tolerance and compliance may be recommended in Sjögren's patients.	INSUFFICIENT	WEAK
5. Smoking cessation is recommended in all Sjögren's patients.	INTERMEDIATE	STRONG
6A. In Sjögren's patients with symptomatic small airway disease, bronchoscopic biopsy is not recommended as part of routine assessment or evaluation.	INSUFFICIENT	STRONG
6B. In Sjögren's patients with symptomatic small airway disease, complete pulmonary function testing must be performed to assess severity of small airways disease, and HRCT imaging with additional expiratory views can be helpful in suggesting its presence.	INSUFFICIENT	STRONG
7. In Sjögren's patients with small airways disease, time-limited empiric therapy in newly diagnosed and previously untreated disease may include: <ul style="list-style-type: none"> <li>● A short course of systemic steroids for 2-4 weeks with a repeat spirometry to determine reversibility, especially if uncontrolled asthma is suspected</li> <li>● Nebulized or inhaled short or long-acting bronchodilators and/or inhaled corticosteroids if there is physiologic obstruction</li> <li>● Short course (i.e. 2-3 months) of empiric macrolide antibiotics (most commonly azithromycin 250mg three days a week) for persistent, non-reversible, symptomatic</li> </ul>	LOW	WEAK



bronchiolitis		
8. It is recommended that Sjögren's patients with clinically relevant bronchiectasis be treated similarly to those with primary or secondary bronchiectasis of other etiologies and may include any of the following: <ul style="list-style-type: none"> <li>● Mucolytic agents/expectorants</li> <li>● Nebulized saline or hypertonic saline</li> <li>● Oscillatory positive expiratory pressure (PEP)</li> <li>● Postural drainage</li> <li>● Mechanical high frequency chest wall oscillation (HFCWO) therapies</li> <li>● Chronic macrolides in those without non-tuberculous mycobacterium (NTM) colonization or infection</li> </ul>	LOW	STRONG

**Figure 2: Evaluation and management of Sjögren's patients who exhibit symptoms and/or physical examination signs of airways disorders (provided in jpg file)**

**Legend:**

**Figure 2:** Evaluation and management of patients with Sjögren's who exhibit symptoms and/or physical examination signs of pulmonary involvement. Refer to Figure 1 for details regarding PFTs and HRCT examinations.

**Abbreviations:** Same as Figure 1 plus COPD = chronic obstructive pulmonary disease.

**References:**

1. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. *J Allergy Clin Immunol.* 2007 Nov;120(5 Suppl):S94-138.
2. Qaseem A et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. *Ann Intern Med.* 2011 Aug 2;155(3):179-91. doi: 10.7326/0003-4819-155-3-201108020-00008.

**Interstitial lung disease**

Most Sjögren's patients who have ILD exhibit pulmonary symptoms such as shortness of breath, cough, sputum production, or chest pain.<sup>6</sup> Symptom severity varies from asymptomatic to minimal dyspnea on exertion to severe. The onset of ILD increases over time with one study showing a prevalence of 10% within the first year of diagnosis and 20% after five years.<sup>8</sup> Among Sjögren's patients with ILD, specific subtypes that have been reported include: nonspecific interstitial pneumonia (NSIP) 45%, respiratory bronchiolitis 25%, usual interstitial pneumonia

(UIP) 16%, lymphoid interstitial pneumonia (LIP) 15%, organizing pneumonia (OP) 7%, amyloid 6%, and lymphoma 4%.<sup>6</sup>

Cystic lung disease is found more commonly in Sjögren's as compared to the other connective tissue diseases (CTDs). Martinez-Balzano *et al* reported that cystic lung disease was associated with older age, a diagnosis of secondary Sjögren's, and elevated anti-SSA (or Ro) antibody,<sup>25</sup> whereas Lechtman *et al* reported a higher frequency of anti-SSB (or La) antibody.<sup>26</sup> Pulmonary function testing was nonspecific, and no significant radiographic progression was noted (n=12) after a median follow-up of four years. Two patients had secondary infections complicating the cysts, but pneumothoraces appeared to be an uncommon presentation of cystic lung disease. The prognosis of cystic lung disease in Sjögren's depends on the specific histopathologic findings. Cystic lung disease in Sjögren's is most commonly secondary to LIP/follicular bronchiolitis (FB) but might also suggest the presence of amyloid or MALT lymphoma, especially if associated with concomitant nodules.<sup>27</sup>

A large proportion of the ILDs in Sjögren's tend to follow an indolent course. However, ILD with a UIP pattern in Sjögren's can be progressive and portends a worse prognosis.<sup>28-29</sup> Acute exacerbations of NSIP and UIP have been reported and can precipitate respiratory failure and death. Most cases do not require biopsy confirmation, as the diagnosis usually can be made based on HRCT and PFTs, and treatment is not always necessary.<sup>28</sup> Ito *et al*<sup>30</sup> reported that mortality is associated with decreased baseline PaO<sub>2</sub> and presence of microscopic honeycombing. A large retrospective cohort from Taiwan<sup>31</sup> of 4,954 Sjögren's patients reported the incidence of respiratory failure was higher than in non-Sjögren's patients, regardless of sex, age, and comorbidities. Respiratory failure in primary Sjögren's was most commonly attributed

to ILD (25%), followed by small airway disease (22%), desiccation of upper respiratory tract (17%), and large airway obstruction (8%).

When obtaining baseline PFTs, it should be noted that discordance between PFT abnormalities, degree of symptoms, and HRCT findings can occur.<sup>7,32-33</sup> Additionally, patients with ILD have variable natural history of disease progression. While evidence is unavailable on the frequency or duration of PFTs in Sjögren's-ILD, TRG members typically perform full PFTs at the time of the initial evaluation followed by repeat assessment every 3-6 months, especially in the first 1-2 years. The frequency of subsequent testing is dictated by an individual patient's pace of disease progression.

Many of the pharmacological interventions are based on the severity of the Sjögren's-ILD. While no standard definition exists for staging, the panel bases severity on the pulmonary domain disease activity defined by EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI), which uses symptoms defined by the New York Heart Association (NYHA) Functional Classification, imaging, and PFT results.<sup>34</sup> In general, moderate and severe/high disease activity is gauged as follows:

- Moderate: shortness of breath on exercise (NHYA II) or PFTs restricted to Forced Vital Capacity (FVC) between 60-80% predicted or DLCO between 40-70% predicted.
- Severe/High: shortness of breath at rest (NHYA III, IV) or PFTs with FVC < 60% predicted or DLCO < 40% predicted.

Close follow-up is required for all pharmacological treatments. Additionally, the TRG and CEP recognized the paucity of specific clinical trials dedicated to Sjögren's-ILD as a significant and high priority research gap. The recommendations (Table 4) and the clinical pathway (Figure 3)

are based on extrapolation of current guidelines and literature on non-Sjögren's ILDs, including important recent clinical trials on the potential role of antifibrotic therapies (e.g. nintedanib) in CTD-ILD.<sup>35</sup>

Therapies reported for Sjögren's-ILD along with their mechanism of action, common side effects, and level and strength of recommendation are summarized in e-Appendix 7. Nintedanib, an antifibrotic, was recently approved for 'progressive' fibrotic ILD phenotypes, which may also include those associated with Sjögren's and other CTDs. Common side effects include diarrhea or loose stools and gastrointestinal upset, the former commonly treated with loperamide. Medication monitoring involves assessing for drug-induced liver injury with baseline and serial evaluation of transaminases and total bilirubin.

**Table 4: Recommendations for Interstitial Lung Disease (ILD) in Sjögren's Patients**

<b>Recommendations: ILD: Diagnosis, Evaluation and Management</b>	<b>Strength of Evidence</b>	<b>Strength of Recommendation</b>
1. In a Sjögren's patient with suspected ILD, an HRCT with expiratory views is recommended.	HIGH	STRONG
2. In a Sjögren's patient with suspected ILD, oximetry testing is recommended as part of a patient's initial evaluation.	HIGH	STRONG
3. Baseline pulmonary function tests (PFTs) must be performed in all Sjögren's patients with suspected or established ILD and followed initially at 3-6 month intervals for at least 1 year. Subsequent testing requires consideration of the type of ILD, the clinical course, and the pace of change noted on the serial PFTs. The baseline PFTs should include lung volumes by body plethysmography, spirometry, diffusing capacity, and oxygen saturations at rest and exercise.	LOW	STRONG
4. In a Sjögren's patient with ILD, a surgical lung biopsy is not routinely recommended. A lung biopsy may be considered following a multidisciplinary review where a biopsy may have significant management implications, such as in: <ul style="list-style-type: none"> <li>• Neoplastic and non-neoplastic lymphoproliferative disorder</li> </ul>	INTERMEDIATE	STRONG

<ul style="list-style-type: none"> <li>• Other cancers</li> <li>• Amyloid</li> <li>• Progressive deterioration and a suspected infection failing empiric therapies where less invasive testing proved nondiagnostic</li> </ul>		
5. If a Sjögren's-ILD patient is asymptomatic for lung disease or demonstrates minimal impairment on PFTs or HRCT, serial monitoring by PFTs is recommended every 3-6 months to establish disease trajectory and initiation of pharmacotherapy only if serial studies document a significant decline in lung function.	INTERMEDIATE	STRONG
<b>Recommendations: ILD: Non-Pharmacological and Other Management</b>	<b>Strength of Evidence</b>	<b>Strength of Recommendation</b>
<b>1. Vaccination:</b> All Sjögren's patients must be immunized against influenza and pneumococcal infection (Pneumovax and Prevnar) in accordance with Centers for Disease Control (CDC) guidelines.	HIGH	STRONG
<b>2. Pneumothorax and Cystic Lung Disease:</b> Because a Sjögren's patient with cystic lung disease might have an increased risk of pneumothorax, patients and caregivers/family must be educated about signs and symptoms of pneumothorax and instructed to seek immediate medical attention if they experience signs or symptoms.	INTERMEDIATE	STRONG
<b>3. Pulmonary Rehab and ILD:</b> In a symptomatic Sjögren's patient with ILD and impaired pulmonary function, referral for pulmonary rehabilitation is recommended.	INTERMEDIATE	STRONG
<b>4. Oxygen and ILD:</b> In a Sjögren's patient with suspected ILD and clinically significant resting hypoxemia (defined by resting O <sub>2</sub> sat <88%, PaO <sub>2</sub> <55 or <60 with complication of chronic hypoxemia such as cor pulmonale), long-term oxygen therapy is recommended.	INTERMEDIATE	STRONG
<b>5A. Air Travel and ILD:</b> In a Sjögren's-ILD patient considering air travel, the need for supplemental oxygen should be evaluated by a physician.	INTERMEDIATE	MODERATE
<b>5B. Air Travel and ILD:</b> In a Sjögren's patient with ILD, discouraging air travel	INTERMEDIATE	STRONG

is not recommended unless the patient develops signs and symptoms of pneumothorax or new onset/unexplained chest pain or dyspnea prior to boarding.		
<b>6. Lung Transplant and ILD:</b> In a Sjögren's patient with ILD whose condition is advanced with resting hypoxia or whose lung function is rapidly deteriorating, lung transplant evaluation is recommended.	INTERMEDIATE	STRONG
<b>Recommendations:</b> <b>ILD: Pharmacological Interventions</b>	<b>Strength of Evidence</b>	<b>Strength of Recommendation</b>
<b>1A. Symptomatic/ Moderate-Severe ILD – Systemic Corticosteroids:</b> In Sjögren's patients with symptomatic ILD with moderate to severe impairment on lung function, imaging, or in gas-exchange and especially in Organizing Pneumonia (OP), systemic steroids should be considered as a first-line treatment at a dosage based on the clinical context and disease severity, with standard dosage being 0.5-1.0 mg/kg.	INTERMEDIATE	MODERATE
<b>1B. Cautions for Systemic Corticosteroids:</b> In a Sjögren's patient with ILD or related disorder and considering use of systemic steroids, patients and healthcare providers must be aware of the following risks/potential harms: <b>Potential short-term side effects:*</b> <ul style="list-style-type: none"> <li>● Glucose intolerance</li> <li>● Avascular necrosis</li> <li>● Mineralocorticoid effect, leading to potential fluid retention and/or hypertension</li> <li>● Myopathy</li> <li>● Psychological, including hyperactivity, insomnia, psychosis</li> <li>● Pancreatitis</li> <li>● Hypertension</li> <li>● Truncal obesity</li> <li>● Acne</li> <li>● Hematopoietic, including leukocytosis</li> <li>● Ecchymosis</li> <li>● Acanthosis nigricans</li> </ul> <b>Potential long-term side effects:</b> <ul style="list-style-type: none"> <li>● Osteoporosis</li> <li>● Diabetes</li> <li>● Adrenal insufficiency</li> <li>● Gastrointestinal symptoms, including peptic ulcer, hepatic steatosis</li> </ul>	HIGH	STRONG

<ul style="list-style-type: none"> <li>● Ophthalmological, including glaucoma, cataract</li> <li>● Hyperlipidemia</li> <li>● Congenital malformation in utero exposure (very rare)</li> <li>● Growth suppression (only in pediatrics)</li> </ul>		
<p><b>2A. Symptomatic/ Moderate-Severe ILD – Mycophenolate mofetil (MMF) or Azathioprine (AZA):</b> In a Sjögren’s patient with symptomatic ILD with moderate to severe impairment as determined by lung function testing, imaging, or gas-exchange, mycophenolate (MMF) or azathioprine (AZA) should be considered when long-term steroid use is contemplated and steroid-sparing immunosuppressive therapy is required.</p>	INTERMEDIATE	MODERATE
<p><b>2B. Cautions for Azathioprine:</b> In a Sjögren’s patient with ILD or related disorder and considering use of azathioprine (AZA), patients and healthcare providers must be aware of potential risks for drug-induced pneumonitis, gastrointestinal upset, hepatotoxicity, bone marrow suppression, rash, and hypersensitivity syndrome. Testing for Thiopurine methyltransferase (TPMT) activity or genotype before initiating AZA is recommended to reduce the risk of severe, life-threatening leucopenia due to complete lack of TPMT activity.*</p>	HIGH	STRONG
<p><b>2C. Cautions for Mycophenolate Mofetil:</b> In a Sjögren’s patient with ILD or related disorder and considering use of mycophenolate mofetil (MMF), patients and healthcare providers must be aware of potential side effects, including nausea, diarrhea, hepatotoxicity, and bone marrow suppression.*</p>	HIGH	STRONG
<p><b>3. Symptomatic/ Moderate-Severe ILD – Maintenance therapies:</b> Following initial treatment for Sjögren’s patients with ILD who are symptomatic and in whom PFTs or HRCT demonstrated moderate-severe impairment, first-line maintenance drugs should be either mycophenolate (MMF) or azathioprine (AZA).</p>	LOW	MODERATE
<p><b>4A. Symptomatic/ Moderate-Severe ILD – Second-Line Therapies:</b> If initial treatment with mycophenolate (MMF) or azathioprine (AZA) is insufficient or not tolerated in Sjögren’s patients with ILD who are symptomatic and in whom PFTs or HRCT demonstrated moderate-severe impairment, subsequent second line maintenance drugs may include rituximab</p>	LOW	WEAK

(RTX) and calcineurin inhibitors, cyclosporine or tacrolimus.		
<p><b>4B. Cautions for Rituximab (RTX):</b>  In a Sjögren's patient with ILD considering use of rituximab (RTX), patients and healthcare providers must be aware of the following potential risks/harms, although rare:*</p> <ul style="list-style-type: none"> <li>● Pneumonitis</li> <li>● Worsening of ILD</li> <li>● Infusion reactions</li> <li>● Tumor lysis syndrome in those with NHL</li> <li>● Bacterial, viral or fungal infections including: <ul style="list-style-type: none"> <li>○ Hepatitis B reactivation with possible fulminant hepatitis</li> <li>○ Progressive multifocal leukoencephalopathy (PML)</li> </ul> </li> <li>● Hypogammaglobulinemia</li> <li>● Cytopenias</li> <li>● Severe mucocutaneous reactions</li> <li>● Bowel obstruction and perforation</li> <li>● Cardiac arrhythmias and angina</li> <li>● In pregnancy and nursing, risk vs benefit must be carefully considered</li> <li>● Avoid live vaccines with rituximab</li> </ul>	HIGH	STRONG
<p><b>5. Symptomatic/ Moderate-Severe Sjögren's-ILD – Antifibrotic drugs:**</b>  The use of anti-fibrotic therapy such as nintedanib should be tried as a second-line maintenance therapy either alone or in combination with immunomodulatory agents in Sjögren's patients with progressive fibrotic ILD who are symptomatic and in whom PFTs or HRCT demonstrated moderate-severe impairment.</p>	LOW	MODERATE
<p><b>6. Rapidly progressive or exacerbating ILD – IV Steroids:</b>  In Sjögren's patients with ILD who are rapidly progressive or present with acute respiratory failure, a trial of high dose corticosteroids (such as intravenous methylprednisolone) is recommended. Alternative etiologies, such as infections or lymphoproliferative disorders, must be considered.</p>	INTERMEDIATE	STRONG
<p><b>7A. Symptomatic/Refractory, rapidly progressive or exacerbating ILD – Cyclophosphamide (CYP):</b>  In a Sjögren's patient with ILD who has acute or subacute hypoxic respiratory failure requiring hospitalization, despite initial therapies, rituximab (RTX) or cyclophosphamide (CYP) should be considered in addition to high dose corticosteroids.</p>	LOW	MODERATE



<p><b>7B. Cautions for Cyclophosphamide (CYP):</b>          In Sjögren's with ILD when cyclophosphamide is considered, the significant risks must be assessed*, and Pneumocystis jiroveci prophylaxis provided. Risk of bladder cancer can be greatly reduced with intravenous versus oral route.</p>	INTERMEDIATE	STRONG
<p><b>8. Drug-induced lung disease:</b>          Clinicians and patients must be aware of pulmonary complications associated with medications used in Sjögren's and related CTDs, particularly when patients are progressive or refractory to therapies. Complications may include infections, malignancies, bronchospasm, and drug-induced ILD, and may require bronchoscopy, biopsy and/or withdrawal of the medication. In addition to medication withdrawal, corticosteroids may be used if significant symptoms and respiratory impairment are present. While the risk is low for most agents (~1%), healthcare providers should keep in mind that medications used to treat Sjögren's have been associated with drug-induced ILD, including:</p> <ul style="list-style-type: none"> <li>● TNF-alpha inhibitors</li> <li>● Sulfasalazine</li> <li>● Cyclophosphamide</li> <li>● Rituximab</li> <li>● Leflunomide</li> <li>● Methotrexate</li> <li>● Sulfonamides</li> </ul>	INTERMEDIATE	STRONG

\*Refer to the FDA label for additional information.

\*\*The antifibrotic, nintedanib, was FDA-approved for progressive fibrotic ILD just as these recommendations went to consensus. This factor, in addition to the authors' awareness of minimal experience with antifibrotics in autoimmune disease, precluded inclusion of a Recommendation listing cautions for antifibrotics. Please consult the PDR for potential risks and side effects.

**Figure 3: Evaluation and management of patients with Sjögren's who exhibit symptoms and/or physical examination signs of interstitial lung disease (Provided in jpg file)**

**Legend:**

Refer to Figure 1 for details regarding PFTs and HRCT examinations.

\* The dose and duration of corticosteroids in Sjögren's ILD is not standardized. The panel proposes a dose not to exceed 60mg daily of prednisone with a slow taper over weeks-months. In rapidly progressive ILD, or acute respiratory failure, consider pulse dose intravenous corticosteroids or high dose oral corticosteroids up to 60mg daily of prednisone

\*\* In patients who are not able to successfully taper off corticosteroids, or experience unfavorable adverse effects, or in patients where the length of corticosteroid therapy is predicted to be long-term – steroid sparing agents should be initiated as maintenance therapy.

\*\*\* Condition rapidly deteriorate and require hospitalization

+ Nintedanib is FDA approved for progressive fibrotic lung disease phenotype

++ Calcineurin inhibitor can be considered in patients who are intolerant to the initial maintenance therapy, no evidence to support the superiority in patients who fail the first line therapy.

**Abbreviations:** Same as Figure 1 plus MMF = Mycophenolate, AZA = azathioprine, Rituximab = RTX, Cyclophosphamide = CYP, ILD = Interstitial Lung Disease, PH = pulmonary hypertension

### Lymphoproliferative Disease

Six recommendations were developed on lymphoproliferative disease in Sjögren's (Table 5). Concerns for lymphoma development in Sjögren's, which ranges from 5 to 18%, are delineated in numerous papers.<sup>36-40</sup> Lymphoproliferative involvement of the lungs can present as non-resolving consolidations, focal nodules (particularly in the presence of parotitis), lymphadenopathy, and cystic lesions accompanied by adjacent nodules and may be asymptomatic.

Exam findings of importance include lymphadenopathy and parotitis, particularly when positron emission tomography (PET)-avid parotitis ( $SUV \geq 4.7$ ) is accompanied by lung nodules.<sup>41-42</sup> Focal lung nodules and consolidations are present in approximately a third of Sjögren's patients with pulmonary lymphoma versus 3% without lymphoma.<sup>41</sup> Multiple sub-centimeter lung nodules accompanied by adjacent cystic lesions (typically <1cm in size in peribronchovascular and subpleural distributions) may further indicate a MALT lymphoma with focal amyloidosis.<sup>43</sup> Presence of ILD does not appear to indicate a higher risk for lymphoma.<sup>41</sup>

Sjögren's patients are at a higher risk for both non-neoplastic (e.g. nodular lymphoid hyperplasia, follicular bronchiolitis, lymphoid interstitial pneumonia) and neoplastic monoclonal lymphoproliferative disorders. Approximately 6% of Sjögren's-associated lymphomas may

directly involve the lungs and are most commonly of the MALT type, manifesting as focal nodules, consolidations, and/or masses.<sup>30,41,44</sup> Cystic lesions in the lungs due to amyloid involvement can be associated with Sjögren's, as well as MALT lymphomas and are highly suggestive of Sjögren's.<sup>43</sup> Given the prevalence and increased risk for lymphoproliferative disorders, active clinical surveillance for pulmonary lymphoproliferative complications in Sjögren's is recommended, especially for Sjögren's patients who are at high risk for lymphoma. Known risk factors include persistent salivary gland swelling, vasculitis and palpable purpura, lymphadenopathy, lab findings of low complements (C3 or C4), monoclonal gammopathy, cryoglobulins, anti-SSA (or Ro) and/or anti-SSB (or La), rheumatoid factor, anemia, leukopenia, lymphopenia, neutropenia, thrombocytopenia, elevated serum beta2-microglobulin and/or B-cell Activating Factor (BAFF).<sup>39</sup>

HRCT and PET scan abnormalities are common in Sjögren's with or without lymphomatous complications.<sup>7,41</sup> Multidisciplinary review with oncology can aid in diagnosis and management. MALT lymphomas as well as cystic lung disease associated with Sjögren's often have an indolent course and can be managed conservatively.<sup>25-26,45</sup> Frequency of HRCT monitoring will be variable based on cyst size/appearance and clinical presentation. Accessibility to PET, costs, and insurance coverage should be considered. Many U.S. clinicians may have difficulty obtaining payor authorization for PET if it is not ordered by an oncologist or if malignancy is not yet diagnosed by histopathologic confirmation.

**Table 5: Recommendations for Lymphoproliferative Disease in Sjögren's Patients**

<b>Recommendations: Diagnosis, Evaluation and Management for Lymphoproliferative Disease in Sjögren's Patients</b>	<b>Strength of Evidence</b>	<b>Strength of Recommendation</b>
1. The possibility of lymphoma must be further investigated in a Sjögren's patient with symptoms such as unexplained weight loss, fevers, night sweats, and/or the presence of head and neck lymphadenopathy and/or parotitis.	HIGH	STRONG

2. All Sjögren's patients must be clinically monitored for signs and symptoms of pulmonary lymphoproliferative disorders including lymphoma and amyloid.	HIGH	STRONG
3. In Sjögren's patients suspected of having lymphoproliferative complications, a HRCT chest scan should be considered more appropriate than a baseline CXR at the time of initial diagnosis.	INTERMEDIATE	MODERATE
4. In a Sjögren's patient with pulmonary lesions (nodules >8mm, consolidations, or lymphadenopathy) in whom a neoplasm is suspected, a positron emission tomography (PET) should be considered.	INTERMEDIATE	MODERATE
5. In Sjögren's patients with lymphadenopathy, growing lung nodules, and/or progressive cystic lung disease, a biopsy should be recommended. Clinical and radiographic observation may be appropriate in select patients with incidental subcentimeter nodules, stable cysts, and isolated PET negative subcentimeter lymphadenopathy.	INTERMEDIATE	MODERATE
6. In a Sjögren's patient in whom a neoplasm has been confirmed or suspected, multidisciplinary review involving rheumatologist/primary care physician, pulmonologist, pathologist, radiologist, and hematologist/oncologist is recommended.	LOW	STRONG

## Summary

Pulmonary involvement due to Sjögren's is common and frequently involves upper and lower airways disease, parenchymal or interstitial lung disease, and associated lymphoproliferative disease. A common theme for all of these recommendations, and endorsed by the TRG, is the need for a multidisciplinary approach in the care of Sjögren's patients with suspected or confirmed pulmonary complications, including a rheumatologist, primary care physician, pulmonologist, pathologist, radiologist, and, when appropriate, an oncologist.

While most of the evidence would be considered of low quality due to the lack of randomized, placebo-controlled clinical trials, our recommendations and strength of the recommendations incorporate Sjögren's-specific expertise in pulmonology, rheumatology and

hematology/oncology. Thirty-four recommendations were rated as strong, indicating the extent of agreement that these recommendations reflect best practice, while eleven were rated as moderate and six as weak. The lowest level of agreement for any recommendation was 79% for the weak recommendation to consider performing PFTs to detect underlying pulmonary manifestations in asymptomatic Sjögren's patients. CEP comments primarily cited the burden and expense of obtaining PFTs as well as an improbability of non-pulmonologists ordering such tests due to inadequate awareness of and appreciation for pulmonary manifestations in Sjögren's. Overall, the CEP provided a high level of agreement for the recommendations and strength of the recommendations, with 76 of the 102 questions provided for voting receiving higher than 98% agreement.

Clinical practice guidelines for pulmonary manifestations in Sjögren's may improve early identification, evaluation, and uniformity of care by primary care physicians, rheumatologists and pulmonologists. Full clinical rationales and references developed by the TRG for these recommendations may be viewed in e-Appendix 5. The guidelines process also has led to identification of high priorities for future research (e-Appendix 8). These priorities include epidemiological and risk analyses, blood-based and non-invasive biomarkers, quantitative imaging tools, optimal frequency of repeat PFTs and HRCT testing for each pattern of pulmonary disease, studies on etiology and treatment, and specifically on antifibrotics for Sjögren's-ILD.

**Key References** (A full list of references is available in the online supplement, e-Appendix 9.)

1. Vivino FB. Sjögren's syndrome: Clinical aspects. *Clin Immunol.* 2017;182:48-54. PMID: 28428095.
2. Lackner A, Ficjan A, Stradner MH, et al. It's more than dryness and fatigue: The patient perspective on health-related quality of life in Primary Sjögren's Syndrome - A qualitative study. *PLoS One.* 2017;12(2). PMID: 28182787.

3. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. *Arthritis & Rheum.* 2008;58(1):15-25. PMID: 18163481.
4. Patel R, Shahane A. The epidemiology of Sjögren's syndrome. *Clin Epidemiol.* 2014;6:247-55. PMID: 25114590.
5. Whitacre CC. Sex differences in autoimmune disease. *Nat Immunol.* 2001;2(9):777-80. PMID: 11526384.
6. Ramos-Casals M, Brito- Zerón P, Seror R, et al. Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. *Rheumatology (Oxford).* 2015 Dec;54(12):2230-8. PMID: 26231345.
7. Uffman M, Kiener HP, Bankier AA, Baldt MM, Zontsich T, Herold CJ. Lung manifestation in asymptomatic patients with primary Sjogren syndrome: assessment with high resolution CT and pulmonary function tests. *J Thorac Imaging.* 2001;16(4):282-9. PMID: 11685093.
8. Nannini C, Jebakumar AJ, Crowson CS, Ryu JH, Matteson EL. Primary Sjögren's syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality. *BMJ Open.* 2013;3(11):e003569. PMID: 24282246.
9. Lohrmann C, Uhl M, Warnatz K, et al. High-resolution CT imaging of the lung for patients with primary Sjögren's syndrome. *Eur J Radiol.* 2004 Nov;52(2):137-43. PMID: 15489070.
10. Manfredi A, Sebastiani M, Cerri S, et al. Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement. *Clin Rheumatol.* 2017 Jun;36(6):1261-8. PMID: 28324200.
11. Constantopoulos SH, Papadimitriou CS, Moutsopoulos HM. Respiratory manifestations in primary Sjögren's syndrome. A clinical, functional, and histologic study. *Chest.* 1985 Aug;88(2):226-9. PMID: 4017677.
12. American College of Rheumatology policy and procedure manual for clinical practice guidelines. American College of Rheumatology website: [https://www.rheumatology.org/Portals/0/Files/ACR%20Guideline%20Manual\\_Appendices\\_updated%202015.pdf](https://www.rheumatology.org/Portals/0/Files/ACR%20Guideline%20Manual_Appendices_updated%202015.pdf). Updated January 2015.
13. Carsons SE, Vivino FB, Parke A, Carteron N, Sankar V, Brasington R, Brennan MT, Ehlers W, Fox R, Scofield H, Hammitt KM, Birnbaum J, Kassan S, Mandel S. Treatment Guidelines for Rheumatologic Manifestations of Sjögren's: Use of Biologics, Management of Fatigue & Inflammatory Musculoskeletal Pain. *Arthritis Care Res (Hoboken).* 2017 Apr;69(4):517-27.
14. Somerfield MR, Bohlke K, Browman GP et al. Innovations in American Society of Clinical Oncology Practice Guideline Development. *J Clin Oncol.* 2016 Sep;34(26):32130-20. <https://ascopubs.org/doi/full/10.1200/JCO.2016.68.3524>.
15. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. *Ann Rheum Dis.* 2002 Jun;61(6):554-8. PMID: 12006334
16. Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. *Arthritis Rheumatol.* 2016 Oct 26. PMID: 27785888
17. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med* 2018;198(5):e44-e68. PMID: 30168753.
18. Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. *Lancet Respir Med* 2018;6(2):138-53. PMID: 29154106.
19. Kelly C, Gardiner P, Pal B, Griffiths I. Lung function in primary Sjögren's syndrome: a cross sectional and longitudinal study. *Thorax.* 1991;46(3):180-3. PMID: 2028432.

20. Dođru G, Balkarli A, Dogru A. Chronic non-productive cough in patients with primary Sjögren's syndrome. *Arch Rheumatol*. 2017;32(4):303-8. PMID: 29901004.
21. Koslow M, Kivity S, Vishnevskia-Dai V, Ben-Dov I. Unexplained cough: it is time to rule out Sjögren's syndrome. *Clin Rheumatol* 2018;37(5):1215-22. PMID: 29388084.
22. Irwin RS, French CL, Chang AB, Altman KW, CHEST Expert Cough Panel. Classification of cough as a symptom in adults and management algorithms: CHEST Guideline and Expert Panel Report. *Chest* 2018;153(1):196-209. PMID: 29080708.
23. Nakanishi M, Fukuoka J, Tanaka T, et al. Small airway disease associated with Sjögren's syndrome: Clinico-pathological correlations. *Respir Med* 2011;105:1931-8. PMID: 21903371.
24. Ramos-Casals M, Brito- Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. *Ann Rheum Dis* 2020;79(1):3-18. PMID: 31672775.
25. Martinez-Balzano CD, Touray S, Kopec S. Cystic lung disease among patients with Sjogren syndrome: frequency, natural history, and associated risk factors. *Chest*. 2016;150(3):631-9. PMID: 27231156.
26. Lechtman S, Debray MP, Crestani B, et al. Cystic lung disease in Sjögren's syndrome: An observational study. *Joint Bone Spine*. 2017;84(3):317-21. PMID: 27659405.
27. Baqir M, Kluka EM, Aubry MC, et al. Amyloid-associated Cystic Lung Disease in Primary Sjogren's Syndrome. *Respir Med* 2013;107(4):616-21. PMID: 23402779.
28. Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH. Interstitial lung disease in primary Sjogren syndrome. *Chest*. 2006;130(5):1489-95. PMID: 17099028.
29. Zhang T, Yuan F, Xu L, Sun W, Liu L, Xue J. Characteristics of patients with primary Sjögren's syndrome associated interstitial lung disease and relevant features of disease progression. *Clin Rheumatol*. 2020 May;39(5):1561-68. PMID: 31902032.
30. Ito I, Nagai S, Kitachi M, et al. Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study. *Am J Respir Crit Care Med*. 2005 Mar 15;171(6):632-8. PMID: 15579729.
31. Yeh JJ, Chen HJ, Li TC, et al. Association between Sjögren's syndrome and respiratory failure: put airway, interstitia, and vessels close together: a national cohort study. *PLoS One*. 2014;9(10): e110783. PMID: 25350278.
32. Taouli B, Brauner MW, Mourey I, Lemouchi D, Grenier PA. Thin-section chest CT findings of primary Sjögren's syndrome: correlation with pulmonary function. *Eur Radiol*. 2002;12(6):1504-11. PMID 12042961.
33. Salaffi F, Manganelli P, Carotti M, et al. A longitudinal study of pulmonary involvement in primary Sjögren's syndrome: relationship between alveolitis and subsequent lung changes on high-resolution computed tomography. *Br J Rheumatol*. 1998 Mar;37(3):263-9. PMID: 9566665.
34. Seror R, Bowman SJ, Brito-Zeron P, et al. EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. *RMD Open*. 2015;1(1):e000022. PMID: 26509054.
35. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. *N Engl J Med*. 2019;381(18):1718-27. PMID: 31566307.
36. Theander E, Henriksson G, Ljungberg O, Mandle T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. *Ann Rheum Dis*. 2006;65(6):796-803. PMID: 16284097.
37. Ekström Smedby KE, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. *Blood*. 2008;111(8):4029-38. PMID: 18263783.
38. Voulgarelis M, Ziakas PD, Papageorgiou A, Baimpa E, Tzioufas AG, Moutsopoulos HM. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome. *Medicine (Baltimore)*. 2012;91(1):1-9. PMID: 22198497.
39. Brito-Zerón P, Kostov B, Fraile G, et al. Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. *J Hematol Oncol*. 2017;10(1):90. PMID: 28416003

40. Vasaitis L, Nordmark G, Theander E, et al. Comparison of patients with and without pre-existing lymphoma at diagnosis of primary Sjögren's syndrome. *Scand J Rheumatol.* 2019;48(3):207-12. PMID: 30422723.
41. Keraen J, Blanc E, Besson FL, et al. *Arthritis Rheumatol.* 2019;71(7):1147-57. PMID: 30615273.
42. Fragkioudaki S, Mavragani CP, Moutsopoulos HM. Predicting the risk for lymphoma development in Sjogren syndrome: An easy tool for clinical use. *Medicine (Baltimore)* 2016;95(25):e3766. PMID: 27336863.
43. Zamora AC, White DB, Sykes AM, et al. Amyloid-associated cystic lung disease. *Chest.* 2016;149(5):1223-33. PMID: 26513525.
44. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Conceted Action on Sjögren's Syndrome. *Arthritis Rheum.* 1999 Aug;42(8):1765-72. PMID:10446879.
45. Kim JH, Lee SH, Park J, et al. Primary pulmonary non-Hodgkin's lymphoma. *Jpn J Clin Oncol.* 2004;34(9):510-4. PMID: 15466823.

### **Table and Figures:**

- |          |  |
|----------|--|
| Table 1  | Recommendations for Evaluating Sjögren's Patients  |
| Figure 1 | Respiratory Evaluation for Sjögren's Patients  |
| Table 2  | Evaluation for Potential Sjögren's in Patients with Pulmonary Symptoms   |
| Table 3  | Recommendations for Assessment and Management of Upper and Lower Airway Disease in Sjögren's Patients                                    |
| Figure 2 | Evaluation and management of Sjögren's patients who exhibit symptoms and/or physical examination signs of airways disorders              |
| Table 4  | Recommendations for Interstitial Lung Disease in Sjögren's Patients  |
| Figure 3 | Evaluation and management of patients with Sjögren's who exhibit symptoms and/or physical examination signs of interstitial lung disease |
| Table 5  | Recommendations for Lymphoproliferative Disease in Sjögren's Patients  |

### **e-Appendices:**


- |              |   |
|--------------|---|
| e-Appendix 1 | Literature Search: Search Parameters, MESH Terms, Searches, Quorum Diagram    |
| e-Appendix 2 | Outline with Questions that Lead to Recommendations                           |
| e-Appendix 3 | Rating Tables for Strength of Evidence and for the Strength of Recommendation |



- e-Appendix 4 Consensus Expert Panel (CEP) Members and Voting Results
- e-Appendix 5 Recommendations with Full Clinical Rationales
- e-Appendix 6 Brief Checklist to Evaluate for Pulmonary Involvement in Sjögren's
- e-Appendix 7 Maintenance Therapies for ILD in Sjögren's
- e-Appendix 8 Future Research Priorities
- e-Appendix 9 Full List of References

Journal Pre-proof

Figure 1: Respiratory Evaluation for Sjögren's Patients




• The benefit of obtaining baseline PFTs in asymptomatic Sjögren's patients with regards to long-term outcomes is not clear. This paucity of evidence and the potential costs of the test should be taken into account and discussed with individual patients prior to proceeding with screening PFTs.

Complete PFTs includes spirometry, diffusing capacity of the lung for carbon monoxide (DLCO), lung volumes, ideally measured by body plethysmography

Abbreviations: CXR=Chest X-Ray; HRCT=High Resolution Computed Tomography; PFTs=Pulmonary Function Tests; DLCO=Diffusing Capacity of Lung for Carbon Monoxide

**Figure 2 –  
Evaluation and management of Sjögren's patients who  
exhibit symptoms and/or physical examination signs of airways disorders**



Abbreviations: Same as Figure 1 plus COPD = chronic obstructive pulmonary disease.

**References:**

1. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. *J Allergy Clin Immunol*. 2007 Nov;120(5 Suppl):S94-138.
2. Qaseem A et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. *Ann Intern Med*. 2011 Aug 2;155(3):179-91. doi: 10.7326/0005-4815-155-3-201108000-00006.

Figure 3: Evaluation and management of patients with Sjögren's who exhibit symptoms and/or physical examination signs of interstitial lung disease

